This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ICON Appoints Alan Morgan To Role Of Group President, Clinical Research Services

ICON plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Mr. Alan Morgan to the position of Group President, Clinical Research Services.

Mr. Morgan is currently Group President, ICON Early Phase and Laboratory Services, and prior to that was Chief Operating Officer of the ICON Clinical Research division, having joined ICON in 2006. Alan has over 20 years experience working in both the pharmaceutical and the CRO industries. Prior to joining ICON, he was Vice President and Global General Manager of the Phase II/IV business of MDS Pharma Services, and he has also held senior positions in Covance, Glaxo Wellcome and ICI Pharmaceuticals.

ICON also announced that Ms Linda Meyerson has joined the company as Chief Operating Officer, ICON Clinical Research. Ms Meyerson will report directly to Mr. Morgan and brings over 30 years of pharmaceutical industry experience and drug development knowledge to the organisation. Prior to joining ICON, Ms Meyerson was Vice President, Global Clinical Operations for GlaxoSmithKline, having previously served in a similar global capacity for the Janssen Research Foundation and the RW Johnson Pharmaceutical Research Institute.

ICON also announced that Dr. John Hubbard, the former Group President, Clinical Research Services, is leaving the organisation to take up a senior role in a leading global biopharmaceutical company.

Commenting on the organisational changes, Mr. Peter Gray, CEO ICON plc said, "I would like to welcome Alan to his new role. He has been an outstanding member of our management team, and his deep knowledge of our clinical organisation and broad industry experience will be invaluable as we continue to develop our business." Mr Gray added, “We are also delighted to welcome Linda to our team. Her extensive global drug development experience will be a huge asset to the organisation. We are sorry to lose John Hubbard, and I would like to acknowledge his outstanding contribution to ICON and wish him every success in his new challenging role.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ICLR $69.01 -0.62%
AAPL $128.46 -1.50%
FB $78.97 -1.79%
GOOG $558.40 0.53%
TSLA $203.34 -1.86%


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs